`Medtronic, Inc., Medtronic Vascular, Inc.,
`& Medtronic Corevalve, LLC
`v. Troy R. Norred, M.D.
`Case IPR2014-00395
`
`
`
`Ovid: Bibliographic Records
`
`http:l!gatevvay.ovid.coml‘re|41Dfserver1r'ovidweb.cgi
`
`
`
`Illlediine <1966 to July Week 4 200lJ>
`
`Results of your search: from 4 [1 and 2 and 3] keep 1-3
`Citations available: 3
`
`Citations displayed: 1-3
`
`Citation 1.
`
`Unique Identifier
`9B414?35
`Authors
`
`Wernly JA. Crawford MH.
`Institution
`
`Division of Thoracic and Cardiovascular Surgery, University of New Mexico School of Medicine. Albuquerque,
`USA.
`
`Title
`
`Choosing a prosthetic heart valve. [Review] [59 refs]
`Source
`
`Cardiology Clinics. 16(3):491-504, 1998 Aug.
`Abstract
`
`Although most of the available prosthetic heart valves function remarkably well. the variety of available choices
`attests to the inability of any single one to fulfill the requirements of the ideal valve substitute. The mechanical
`prostheses include the caged-ball. tilting-disc, and bileaflet valves. Tissue valves available in the United States
`are the Carpentier—Edwards and Hancock porcine heterograft valves and the Carpentier-Edwards pericardial
`valve. Review of several large comparative studies on valve performance reveals that the overall results with
`tissue and mechanical valves are about equal at the end of 10 years. The characteristics of each type of valve
`substitute dictate the selection of one prosthesis in preference to others for a particular patient. Mechanical
`prostheses are recommended for patients without contraindications for anticoagulants. Tissue valves are
`reserved for patients over 65 years of age or for patients in whom anticoagulation is contraindicated. Multiple
`other patient-related factors need to be considered in selecting the appropriate valve, including the
`psychosocial situation and patient preference. [References 59]
`
`citation 2.
`
`Unique Identifier
`98339145
`Authors
`
`Hirai S. Fukunaga S. Sueshiro M. Watari M. Sueda T. Matsuura Y.
`Institution
`
`First Department of Surgery, Hiroshima Unviersity School of Medicine, Japan.
`
`Title
`
`Assessment of a new silicone tri-leaflet valve seamlessly assembled with blood chamber for a low-cost
`ventricular assist device.
`Source
`
`Hiroshima Journal of Medical Sciences. 4'r'(2):47-55, 1998 Jun.
`Abstract
`
`We have developed a practical, low-cost ventricular assist device (VAD) comprising a newly designed blood
`chamber with a silicone lenticular sac and two silicone tri-leaflet valves (STV). made en bloc. This new VAD is
`seamless, can be made cost-effectively and assembled with the blood chamber and valve as one body. This
`novel design should reduce the incident of thrombus formation because of the absence of a junction at the
`connecting ring and because of the use of flexible silicone materials which have both antithrombogenecity and
`biocompatibility. in in vitro hemodynamics testing, a batch of 3 consecutively manufactured VADS with STVs
`underwent hydrodynamic functional testing. These showed less regurgitation, a lower value of water hammer
`
`1of2
`
`Eil'15r'0D 12:46 PM
`
`
`
`NORRED EXHIBIT 2211 - Page 2
`NORRED EXHIBIT 2211 - Page 2